Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast Limited has announced a change in the director’s interest, specifically involving Gregory George. The change includes the acquisition of 50,000 American Depositary Shares (ADS) and the expiry of a put option over the same amount. This update reflects ongoing adjustments in the company’s director-level securities holdings, which could influence stakeholder perceptions and the company’s market dynamics.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on the development and commercialization of innovative cellular medicines. The company primarily works on regenerative medicine products aimed at treating serious and life-threatening conditions.
YTD Price Performance: -31.82%
Average Trading Volume: 400,962
Technical Sentiment Signal: Sell
Current Market Cap: $1.32B
Learn more about MSB stock on TipRanks’ Stock Analysis page.